Surgery Partners Q1 2024 Adj EPS $0.10 Beats $0.07 Estimate, Sales $717.400M Beat $698.031M Estimate
Portfolio Pulse from Benzinga Newsdesk
Surgery Partners (NASDAQ:SGRY) reported Q1 2024 adjusted EPS of $0.10, surpassing the $0.07 estimate, with sales of $717.4M exceeding the $698.031M forecast. This represents a 7.69% increase in sales compared to the same period last year.
May 07, 2024 | 11:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Surgery Partners reported a strong Q1 2024 performance with earnings and sales surpassing estimates, indicating robust financial health and operational efficiency.
The positive earnings and sales beat for Surgery Partners in Q1 2024 suggest a strong financial and operational performance, likely leading to increased investor confidence and potential upward movement in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100